Mankind Pharma Limited — Others, 31-07-2025: Cessation

Mankind Pharma has announced a board meeting where it approved the financial results for the quarter ended June 30, 2025, reporting a consolidated revenue of ₹3,570.35 Cr and a profit of ₹444.62 Cr. The company also declared an interim dividend of ₹1 per equity share. Strategically, the board approved acquiring the Women Health Rx Portfolio from its wholly-owned subsidiary, Bharat Serums and Vaccines, to boost operational efficiency. Additionally, the company plans to raise up to ₹1,000 Cr in short-term funds and noted the Chief Marketing Officer's resignation.